BIOGEN INC. Accrued Royalties, Current
BIOGEN INC. (BIIB) had Accrued Royalties, Current of $320.20 million as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities, Current
us-gaap:AccruedRoyaltiesCurrent · last filed 2025-10-30
- 2025-09-30: Accrued Royalties, Current $320.20M.
- 2025-06-30: Accrued Royalties, Current $200.30M.
- 2025-03-31: Accrued Royalties, Current $166.90M.
- 2024-12-31: Accrued Royalties, Current $190.20M.
| Period end | Accrued Royalties, Current |
|---|---|
| 2025-09-30 | $320.20M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $200.30M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $166.90M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $190.20M 10-Q · filed 2025-10-30 |
| 2024-09-30 | $178.70M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $193.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $161.50M 10-Q · filed 2024-04-24 |
| 2023-12-31 | $191.50M 10-Q · filed 2024-10-30 |
| 2023-09-30 | $202.80M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $205.00M 10-Q · filed 2023-07-25 |
| 2023-03-31 | $183.90M 10-Q · filed 2023-04-25 |
| 2022-12-31 | $209.40M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $208.60M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $216.20M 10-Q · filed 2022-07-20 |
| 2022-03-31 | $216.00M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $234.70M 10-Q · filed 2022-10-25 |
| 2021-09-30 | $238.90M 10-Q · filed 2021-10-20 |
| 2021-06-30 | $240.30M 10-Q · filed 2021-07-22 |
| 2021-03-31 | $212.50M 10-Q · filed 2021-04-22 |
| 2020-12-31 | $218.50M 10-Q · filed 2021-10-20 |
| 2020-09-30 | $222.80M 10-Q · filed 2020-10-21 |
| 2020-06-30 | $203.00M 10-Q · filed 2020-07-22 |
| 2020-03-31 | $209.90M 10-Q · filed 2020-04-23 |
| 2019-12-31 | $220.90M 10-Q · filed 2020-10-21 |
| 2019-09-30 | $222.30M 10-Q · filed 2019-10-22 |
| 2019-06-30 | $212.80M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $195.00M 10-Q · filed 2019-04-24 |
| 2018-12-31 | $224.70M 10-K · filed 2020-02-06 |
| 2018-09-30 | $226.30M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $218.20M 10-Q · filed 2018-07-24 |
| 2018-03-31 | $194.60M 10-Q · filed 2018-04-24 |
| 2017-12-31 | $206.70M 10-K · filed 2019-02-06 |
| 2017-09-30 | $190.80M 10-Q · filed 2017-10-24 |
| 2017-06-30 | $195.80M 10-Q · filed 2017-07-25 |
| 2017-03-31 | $181.00M 10-Q · filed 2017-04-25 |
| 2016-12-31 | $195.80M 10-K · filed 2018-02-01 |
| 2016-09-30 | $209.00M 10-Q · filed 2016-10-26 |
| 2016-06-30 | $183.70M 10-Q · filed 2016-07-21 |
| 2016-03-31 | $161.00M 10-Q · filed 2016-04-21 |
| 2015-12-31 | $167.90M 10-K · filed 2017-02-02 |
| 2015-09-30 | $154.90M 10-Q · filed 2015-10-21 |
| 2015-06-30 | $161.90M 10-Q · filed 2015-07-24 |
| 2015-03-31 | $150.40M 10-Q · filed 2015-04-24 |
| 2014-12-31 | $172.40M 10-K · filed 2016-02-03 |
| 2014-09-30 | $173.00M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $190.00M 10-Q · filed 2014-07-23 |
| 2014-03-31 | $131.30M 10-Q · filed 2014-04-23 |
| 2013-12-31 | $160.70M 10-K · filed 2015-02-04 |
| 2013-09-30 | $117.30M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $113.50M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $42.80M 10-Q · filed 2013-04-25 |
| 2012-12-31 | $45.20M 10-K · filed 2014-02-06 |
| 2012-09-30 | $45.30M 10-Q · filed 2012-10-25 |
| 2012-06-30 | $48.90M 10-Q · filed 2012-07-24 |
| 2012-03-31 | $43.20M 10-Q · filed 2012-05-01 |
| 2011-12-31 | $47.40M 10-K · filed 2013-02-05 |
| 2011-09-30 | $42.90M 10-Q · filed 2011-10-28 |
| 2011-06-30 | $40.00M 10-Q · filed 2011-07-26 |
| 2010-12-31 | $45.10M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |